866-997-4948(US-Canada Toll Free)

Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023

Published By :

GlobalData

Published Date : Apr 2015

Category :

Cancer

No. of Pages : 191 Pages

Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023

Summary

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreons Provenge, Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas Xtandi, and Bayers Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.

The 5EU is the second largest market for prostate cancer, after the US. This strong growth will be a result of the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Prostate Cancer market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prostate Cancer.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.2 Staging 14
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment Overview 20
4.1.1 Screening and Diagnosis 20
4.1.2 Treatment Guidelines and the Leading Prescribed Drugs 22
4.1.3 Clinical Practice 24
4.2 France 34
4.3 Germany 35
4.4 Italy 36
4.5 Spain 37
4.6 UK 38
5 Competitive Assessment 39
5.1 Overview 39
5.2 Product Profiles - Major Brands, Targeted Therapies 40
5.2.1 Zytiga (abiraterone acetate) 40
5.2.2 Xtandi (enzalutamide) 46
5.2.3 Xofigo (radium 223 dichloride) 51
5.3 Product Profiles - Major Brands, Chemotherapies 57
5.3.1 Jevtana (cabazitaxel) 57
5.4 Product Profiles - Major Brands, Therapeutic Vaccines 61
5.4.1 Provenge (sipuleucel-T) 61
5.5 Product Profiles - Major Brands, Hormone Therapies 65
5.5.1 Zoladex (goserelin acetate) 65
5.5.2 Lupron Depot (leuprolide acetate) 68
5.5.3 Eligard (leuprolide acetate) 71
5.5.4 Trelstar (triptorelin acetate) 73
5.5.5 Firmagon (degarelix) 75
5.5.6 Casodex (bicalutamide) 78
5.6 Product Profiles - Major Brands, Bone Therapies 81
5.6.1 Zometa (zoledronic acid) 81
5.6.2 Xgeva (denosumab) 83
6 Unmet Need and Opportunity 87
6.1 Overview 87
6.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 88
6.2.1 Unmet Need 88
6.2.2 Gap Analysis 89
6.2.3 Opportunity 90
6.3 Therapeutic Options for nmCRPC Patients 90
6.3.1 Unmet Need 90
6.3.2 Gap Analysis 91
6.3.3 Opportunity 91
6.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance 92
6.4.1 Unmet Need 92
6.4.2 Gap Analysis 93
6.4.3 Opportunity 94
6.5 Defining the Best Sequence of Drugs to Manage mCRPC 94
6.5.1 Unmet Need 94
6.5.2 Gap Analysis 95
6.5.3 Opportunity 96
7 Pipeline Assessment 97
7.1 Overview 97
7.2 Product Profiles Immunotherapies 100
7.2.1 Yervoy (ipilimumab) 100
7.2.2 ProstVac 106
7.2.3 ProstAtak 111
7.2.4 DCVAC/PCa 116
7.2.5 ITK1 121
7.3 Product Profiles - Targeted Therapies 126
7.3.1 Custirsen Sodium 126
7.3.2 Tasquinimod 131
7.3.3 ARN-509 136
7.3.4 ODM-201 140
8 Market Outlook 146
8.1 5EU 146
8.1.1 Forecast 146
8.1.2 Key Events 150
8.1.3 Drivers and Barriers 151
9 Appendix 152
9.1 Bibliography 152
9.2 Abbreviations 171
9.3 Methodology 176
9.4 Forecasting Methodology 176
9.4.1 Diagnosed Prostate Cancer Patients 176
9.4.2 Percentage Drug-Treated Patients 177
9.4.3 Drugs Included in Each Therapeutic Class 177
9.4.4 Launch and Patent Expiry Dates 178
9.4.5 General Pricing Assumptions 179
9.4.6 Individual Drug Assumptions 180
9.4.7 Pricing of Pipeline Agents 183
9.5 Primary Research - KOLs Interviewed for This Report 185
9.6 Primary Research - Prescriber Survey 187
9.7 About the Authors 188
9.7.1 Analyst 188
9.7.2 Director of Oncology 188
9.7.3 Epidemiologist 189
9.7.4 Global Head of Healthcare 189
9.8 About GlobalData 190
9.9 Disclaimer 190

1.1 List of Tables
Table 1: TNM Classification of Prostate Cancer 16
Table 2: Prostate Cancer Staging 17
Table 3: Risk-Group Classifications Used in Prostate Cancer 18
Table 4: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014 22
Table 5: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014 23
Table 6: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014 24
Table 7: Diagnosis and Treatment of Prostate Cancer, Country Profile - France 34
Table 8: Diagnosis and Treatment of Prostate Cancer, Country Profile - Germany 35
Table 9: Diagnosis and Treatment of Prostate Cancer, Country Profile - Italy 36
Table 10: Diagnosis and Treatment of Prostate Cancer, Country Profile - Spain 37
Table 11: Diagnosis and Treatment of Prostate Cancer, Country Profile - UK 38
Table 12: Leading Branded Drugs Used to Treat Prostate Cancer, 2014 40
Table 13: Product Profile - Zytiga 42
Table 14: Zytiga SWOT Analysis, 2014 44
Table 15: Global Sales Forecasts ($m) for Zytiga, 20132023 45
Table 16: Product Profile - Xtandi 48
Table 17: Xtandi SWOT Analysis, 2014 50
Table 18: Global Sales Forecasts ($m) for Xtandi, 20132023 51
Table 19: Product Profile - Xofigo 54
Table 20: Xofigo SWOT Analysis, 2014 55
Table 21: Global Sales Forecasts ($m) for Xofigo, 20132023 56
Table 22: Product Profile - Jevtana 58
Table 23: Jevtana SWOT Analysis, 2014 59
Table 24: Global Sales Forecasts ($m) for Jevtana, 20132023 60
Table 25: Product Profile - Provenge 63
Table 26: Provenge SWOT Analysis, 2014 64
Table 27: Global Sales Forecasts ($m) for Provenge, 20132023 65
Table 28: Product Profile - Zoladex 66
Table 29: Zoladex SWOT Analysis, 2014 68
Table 30: Product Profile - Lupron 69
Table 31: Lupron SWOT Analysis, 2014 70
Table 32: Product Profile - Eligard 72
Table 33: Eligard SWOT Analysis, 2014 73
Table 34: Product Profile - Trelstar 74
Table 35: Trelstar SWOT Analysis, 2014 75
Table 36: Product Profile - Firmagon 76
Table 37: Firmagon SWOT Analysis, 2014 78
Table 38: Product Profile - Casodex 79
Table 39: Casodex SWOT Analysis, 2014 81
Table 40: Product Profile - Zometa 82
Table 41: Zometa SWOT Analysis, 2014 83
Table 42: Product Profile - Xgeva 85
Table 43: Xgeva SWOT Analysis, 2014 86
Table 44: Unmet Need and Opportunity in Prostate Cancer 88
Table 45: Drugs in Phase III Clinical Trials for Prostate Cancer 99
Table 46: Product Profile - Yervoy 102
Table 47: Yervoy SWOT Analysis, 2014 105
Table 48: Global Sales Forecasts ($m) for Yervoy, 20132023 106
Table 49: Product Profile - ProstVac 107
Table 50: ProstVac SWOT Analysis, 2014 110
Table 51: Global Sales Forecasts ($m) for ProstVac, 20132023 111
Table 52: Product Profile - ProstAtak 112
Table 53: ProstAtak SWOT Analysis, 2014 115
Table 54: Global Sales Forecasts ($m) for ProstAtak, 20132023 116
Table 55: Product Profile - DCVAC/PCa 117
Table 56: DCVAC/PCa SWOT Analysis, 2014 120
Table 57: Global Sales Forecasts ($m) for DCVAC, 20132023 121
Table 58: Product Profile - ITK1 122
Table 59: ITK1 SWOT Analysis, 2014 124
Table 60: Global Sales Forecasts ($m) for ITK1, 20132023 125
Table 61: Product Profile - Custirsen Sodium 127
Table 62: Custirsen Sodium SWOT Analysis, 2014 130
Table 63: Global Sales Forecasts ($m) for Custirsen Sodium, 20132023 131
Table 64: Product Profile - Tasquinimod 132
Table 65: Tasquinimod SWOT Analysis, 2014 135
Table 66: Global Sales Forecasts ($m) for Tasquinimod, 20132023 136
Table 67: Product Profile - ARN-509 137
Table 68: ARN-509 SWOT Analysis, 2014 139
Table 69: Global Sales Forecasts ($m) for ARN-509, 20132023 140
Table 70: Product Profile - ODM-201 141
Table 71: ODM-201 SWOT Analysis, 2014 144
Table 72: Global Sales Forecasts ($m) for ODM-201, 2013-2023 145
Table 73: Sales Forecasts ($m) for Prostate Cancer in the 5EU, 2013-2023 148
Table 74: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2013-2023 150
Table 75: 5EU Prostate Cancer Market - Drivers and Barriers, 20132023 151
Table 76: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs 178
Table 77: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs 178
Table 78: Average Body Weight and Surface Area Across the 9MM 180
Table 79: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 187

1.2 List of Figures
Figure 1: Disease Management Flowchart for Prostate Cancer 25
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013-2023 100
Figure 3: Yervoys Clinical Development 102
Figure 4: Potential Clinical and Commercial Positioning of Yervoy 104
Figure 5: ProstVacs Clinical Development 108
Figure 6: Potential Clinical and Commercial Positioning of ProstVac 109
Figure 7: ProstAtaks Clinical Development 113
Figure 8: Potential Clinical and Commercial Positioning of ProstAtak 114
Figure 9: DCVAC/PCas Clinical Development 117
Figure 10: Potential Clinical and Commercial Positioning of DCVAC/PCa 119
Figure 11: ITK1s Clinical Development 122
Figure 12: Potential Clinical and Commercial Positioning of ITK1 124
Figure 13: Custirsen Sodiums Clinical Development 128
Figure 14: Potential Clinical and Commercial Positioning of Custirsen Sodium 129
Figure 15: Tasquinimods Clinical Development 133
Figure 16: Potential Clinical and Commercial Positioning of Tasquinimod 134
Figure 17: ARN-509s Clinical Development 138
Figure 18: Potential Clinical and Commercial Positioning of ARN-509 139
Figure 19: ODM-201s Clinical Development 142
Figure 20: Potential Clinical and Commercial Positioning of ODM-201 143
Figure 21: Sales for Prostate Cancer in the 5EU by Drug Class, 2013-2023 149

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *